CNBX Pharmaceuticals Inc.
CNBX OTC
SEC CIK 1343009
Follow CNBX Pharmaceuticals
Weekly email: filings, results, news
Revenue, last quarter
$0
Net income
−$154.2K
−158.1% vs same quarter last year
EPS, diluted
$0.00
Operating cash flow
−$47.7K
+8.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$314K |
| FY24 | $130.1K | −$695.2K |
| FY23 | $410.2K | −$3.7M |
| FY22 | $30K | −$3.7M |
| FY21 | $0 | −$3.2M |
| FY20 | $7.2K | −$7.5M |
| FY19 | $9.8K | $1.1M |
| FY18 | $9.6K | −$3.8M |
| FY17 | $5.7K | −$1.9M |
| FY16 | $112.5K | −$307.2K |
| FY15 | $0 | −$541.4K |
| FY14 | - | −$270K |
| FY13 | - | −$56.4K |
| FY12 | - | −$1.7K |
| FY11 | - | −$107.3K |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | −448.3% | −534.5% |
| FY23 | −227.1% | −904.6% |
| FY22 | −9860.4% | −12428.2% |
| FY21 | - | - |
| FY20 | −42524.1% | −104337.9% |
| FY19 | −33563% | 11510.4% |
| FY18 | −39670.1% | −39335.7% |
| FY17 | −32616.1% | −34022.5% |
| FY16 | −249.5% | −273% |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | - | - |
- CNBX Pharmaceuticals
- Healthcare median
Show the numbers
| Year | CNBX Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | - | 9.8% |
| FY24 | −534.5% | 10.5% |
| FY23 | −904.6% | 5.3% |
| FY22 | −12428.2% | 12.7% |
| FY21 | - | 10.8% |
| FY20 | −104337.9% | - |
| FY19 | 11510.4% | - |
| FY18 | −39335.7% | - |
| FY17 | −34022.5% | - |
| FY16 | −273% | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | - | - |
News
No stories filed under CNBX Pharmaceuticals yet - coverage appears here as the news feed clusters it.